The online version of this article (doi:10.1186/1471-230X-14-118) contains supplementary material, which is available to authorized users.
This study was funded in part through the Fellows Research Program sponsored by Bristol-Myers Squibb and Laboratory Corporation of America for performance of the Fibrosure test.
MZ and AHT designed the study. MZ, SB, JM, and MG-G acquired the data. MZ, RBD, RKY, and AHT analyzed and interpreted the data. RBD performed statistical analysis of the data. MZ and AHT wrote the manuscript. All authors read and approved the final version of the manuscript.
Noninvasive markers of liver fibrosis have not been extensively studied in patients with chronic hepatitis B virus (HBV) infection. Our aim was to evaluate the capacity of FibroSURE, one of the two noninvasive fibrosis indices commercially available in the United States, to identify HBV infected patients with moderate to severe fibrosis.
Forty-five patients who underwent liver biopsy at a single tertiary care center were prospectively enrolled and had FibroSURE performed within an average interval of 11 days of the biopsy.
Of the 45 patients, 40% were Asian, 40% were African American, and 13% were Caucasian; 27% were co-infected with HIV and 67% had no or mild fibrosis. We found FibroSURE to have moderate capacity to discriminate between patients with moderate to high fibrosis and those with no to mild fibrosis (area under receiver operating characteristic [AUROC] curve = 0.77; 95% confidence interval [CI] [0.61, 0.92]). When we combined the fibrosis score determined by FibroSURE with aspartate aminotransferase (AST) measurements and HIV co-infection status, the discriminatory ability significantly improved reaching an AUROC of 0.90 (95% CI [0.80, 1.00]). FibroSURE also had a good ability to differentiate patients with no or mild from those with moderate to high inflammation (AUROC = 0.83; 95% CI [0.71, 0.95]).
FibroSURE in combination with AST levels has an excellent capacity to identify moderate to high fibrosis stages in chronic HBV-infected patients. These data suggest that FibroSURE may be a useful substitute for liver biopsy in chronic HBV infection.
Jury E: EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol. 2003, 38 (4): 533-540. CrossRef
Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004, 3 (1): 8- CrossRefPubMedPubMedCentral
Bonnard P, Sombie R, Lescure FX, Bougouma A, Guiard-Schmid JB, Poynard T, Cales P, Housset C, Callard P, Le Pendeven C, Drabo J, Carrat F, Pialoux G: Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg. 2010, 82 (3): 454-458. CrossRefPubMedPubMedCentral
- FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B
Rositsa B Dimova
Rhonda K Yantiss
Andrew H Talal
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II